PPARA and metabolic dysfunction-associated steatotic liver disease: LY518674 is a potent agonist of PPARα that has already progressed to clinical trial phases, so based on the pharmacophore of LY518674, Yu et al. reported a novel DY series of PPARα modulators for NAFLD treatment.